Sprache auswählen
NF-κB
NF-κB Molekülinformation
| Englischer Name | Nuclear factor NF-kappa-B complex | Anzahl der inverkehr gebrachten Arzneimittel | 12 |
| Anzahl der klinischen Arzneimittel | 39 | Target-Alias | NF-kappa B |
| Höchste Forschungs- und Entwicklungsphase | Approved | ||
| Englischer Name | Nuclear factor NF-kappa-B complex |
| Target-Alias | NF-kappa B |
| Anzahl der inverkehr gebrachten Arzneimittel | 12 |
| Anzahl der klinischen Arzneimittel | 39 |
| Höchste Forschungs- und Entwicklungsphase | Approved |
NF-κB Produktliste
- Attribut
Cell (2)
- Produktbibliothek
Online (2)
- Spezies
Human (2)
- Etikett
- (2)
- Marker
- (2)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
CHEK-ATF048 |  Human | HEK293 | NF-κB (Luc) HEK293 Reporter Cell |  |  In den Warenkorb legen | ||
SCJUR-STF113 | Human | Jurkat | NF-κB (Luc) Jurkat Reporter Cell | | In den Warenkorb legen |
Gesamtmenge2
- 1
NF-κB Molekülalias
NF-κB, nuclear factor kappa-B
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| NF-kappa-B decoy oligonucleotide | MP-40; MP-41; MP-42; AMS-001; SI-3104; AMG-0101; AMG-0102; AMG-0103; S-414114 | Phase 3 Clinical | Anges Mg, Osaka University | Dermatitis, Atopic; Intervertebral Disc Degeneration | Details |
| RGN-259 | RGN-457; RGN-352; RGN-259; RGN-137; Tβ4; TB4; GBT-101; GBT-201; Thymosin beta 4-16-38; TB4 16-38; Thymosin beta4; Thymosin B4; Fx peptide | Phase 3 Clinical | National Institutes Of Health | Diabetes Mellitus; Dry Eye Syndromes; Epidermolysis Bullosa; Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa, Junctional; Graft vs Host Disease; Keratitis; Myocardial Infarction; Myocardial Ischemia; Pressure Ulcer; Sjogren's Syndrome; ST Elevation Myocardial Infarction; Varicose Ulcer; Xerophthalmia | Details |
| Dazdotuftide | TRS-01 | Phase 3 Clinical | Tarsius Pharma | Glaucoma; Ocular inflammation; Uveitis; Uveitis, Anterior | Details |
| Hypochlorous Acid | PR-022; PR-013 | Phase 3 Clinical | Realm Therapeutics | Cataract; Conjunctivitis, Allergic; Coronavirus Disease 2019 (COVID-19); Dermatitis, Atopic; Endophthalmitis; Virus Diseases | Details |
| ARINA-1 | ARINA-1 | Phase 3 Clinical | Renovion Inc, University Of North Carolina At Chapel Hill | Bronchiectasis; Bronchiolitis Obliterans; Rejection of lung transplantation | Details |
| Bezisterim | HE-3286; NE-3107 | Phase 3 Clinical | Harbor Therapeutics Inc | Alzheimer Disease; Arthritis, Rheumatoid; Brain Injuries, Traumatic; Colitis, Ulcerative; Diabetes Mellitus, Type 2; Insulin Resistance; Parkinson Disease; Post-Acute COVID-19 Syndrome | Details |
| Dimethylaminomicheliolide Fumarate | ACT-001 | Phase 3 Clinical | Tianjin Accendatech Technology Co Ltd | Brain metastases; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Glioblastoma; Glioma; Melanoma; Neuromyelitis Optica; Optic Neuritis; Small Cell Lung Carcinoma; Solid tumours | Details |
| Nanocurcumin (Tehran University of Medical Sciences) | Phase 2 Clinical | Tehran University Of Medical Sciences | Neoplasms; Periapical Diseases | Details | |
| APPA | APPA; AKL-4; AKL-IV; APPA-1 | Phase 2 Clinical | AKL Research & Development Ltd | Osteoarthritis | Details |
| CKBA | CKBA | Phase 2 Clinical | BCY Pharm Co Ltd | Plaque psoriasis; Rosacea; Vitiligo | Details |
| IMR-261 | CXA-10; IMR-261; E-10-NO2-18:1 | Phase 2 Clinical | Complexa Inc | Acute Kidney Injury; Asthma; Glomerulosclerosis, Focal Segmental; Obesity; Phenylketonurias; Pulmonary Arterial Hypertension | Details |
| Manganese butoxyethyl pyridyl porphyrin | BMX-001; MnTnBuOE-2-PyP5+ | Phase 2 Clinical | Duke University | Astrocytoma; Brain metastases; Carcinoma, Squamous Cell; Endometrial Neoplasms; Glioblastoma; Glioma; Head and Neck Neoplasms; Ovarian Neoplasms; Rectal Neoplasms | Details |
| CBL-0137 | CX-137; CBL-0137; CBLC-137; Curaxin-CBL0137 | Phase 2 Clinical | Cleveland Biolabs Inc | Central Nervous System Neoplasms; Diffuse Intrinsic Pontine Glioma; Diffuse midline glioma; Glioblastoma; Hematologic Neoplasms; Lymphoma; Neoplasms; Sarcoma; Skin Melanoma; Solid tumours | Details |
| Zenuzolac | GIT-27; GIT-027; VGX-1027; GLS-1027 | Phase 2 Clinical | Geneone Life Science Inc | Coronavirus Disease 2019 (COVID-19); Pneumonia | Details |
| Parthenolide | NSC-157035 | Phase 2 Clinical | Ashbury Biologicals | Alzheimer Disease; Cognition Disorders; Cognitive Dysfunction; Lymphoma | Details |
| Withaferin A | Phase 2 Clinical | UofL Health | Ovarian Neoplasms | Details | |
| TML-6 | TML-6 | Phase 2 Clinical | Merry Life Biomedical Co Ltd | Alzheimer Disease | Details |
| Proximod | Phase 2 Clinical | Institue Of Materia Medica Chinese Academy Of Medical Science | Arthritis, Rheumatoid | Details | |
| YIV-906 | PHY-906; KD-018 | Phase 2 Clinical | Phytoceutica Inc | Carcinoma, Hepatocellular; Colorectal Neoplasms; Diarrhea; Hepatitis B; Liver Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms | Details |
| Ascorbic Acid/Menadione | Phase 2 Clinical | Ic-Medtech Co, Summa Health System | Joint Diseases; Prostatic Neoplasms | Details | |
| LC-280126 | MIT-001; LC-280126; NecroX-7; LC28-0126 | Phase 2 Clinical | Lg Chemical Ltd | Hematologic Neoplasms; Lymphoma; Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck; ST Elevation Myocardial Infarction; Stomatitis | Details |
| Ginsenoside C-K | IH-901; LCHK-168; KBB-N1 | Phase 1 Clinical | Fudan University, Il-Hwa, Rohto, State Pharmaceutical Administration of Shanghai Institute of Pharmaceutical Industry, Zhejiang Hisun Pharmaceutical Co Ltd | Arthritis, Rheumatoid; Multiple Myeloma | Details |
| ORYN-1001 | ORTD-1; ORYN-1001 | Phase 1 Clinical | Oryn Therapeutics Llc | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19) | Details |
| CKD-712 | CKD-712 | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Sepsis | Details |
| LH-025 | LH-025 | Phase 1 Clinical | Dr August Wolff | Colitis, Ulcerative | Details |
| Xempritolimod | KMRC-011; KMRC011; CNT-101; CNT-102 | Phase 1 Clinical | Korea Institute Of Industrial Technology | Acute Radiation Syndrome; Graft vs Host Disease; Neoplasms; Stomatitis | Details |
| DEN-181 | DEN-181; CurcusomeRA; CurcusomeTMRA | Phase 1 Clinical | Dendright | Arthritis, Rheumatoid | Details |
| ILB-202 | ILB-202; ILB202 | Phase 1 Clinical | Ilias Biologics Inc | Acute Kidney Injury; Intraoperative Complications | Details |
| SFA-001 | SFA-001; SFA-001N | Phase 1 Clinical | SFA Therapeutics Inc, Temple University | Fibrosis; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| Sprayable Hypochlorous Acid (RELIFE) | RLF-TD011 | Phase 1 Clinical | Relief Therapeutics Holding Sa | Epidermolysis Bullosa | Details |
| Reformulated Cepharanthine (Sairiyo Therapeutics Inc) | PD-001; PD001 | Phase 1 Clinical | Sairiyo Therapeutics Inc | Communicable Diseases; Neoplasms | Details |
| RHN-002 | RHN-002; RHN002 | Phase 1 Clinical | RH Nanopharmaceuticals LLC | Anemia, Sickle Cell; Pain, Postoperative | Details |
| RHN-001 | RHN-001; RHN001 | Phase 1 Clinical | RH Nanopharmaceuticals LLC | Details | |
| Hypochlorous Acid/Acetic Acid | SS0350; SS-0350 | Phase 1 Clinical | Softox Solutions As | Leg Ulcer; Varicose Ulcer | Details |
| SHetA2 | Phase 1 Clinical | The University Of Oklahoma | Solid tumours | Details | |
| TLZ-16-CL | TLZ-16-CL | Phase 1 Clinical | Beijing Taizhou Lize Pharmaceutical Technology Co Ltd | Cocaine-Related Disorders; Substance Withdrawal Syndrome | Details |
| Misetionamide | GP-2250 | Phase 1 Clinical | Geistlich Pharma | Pancreatic Neoplasms | Details |
| Anatabine citrate | RCP-006 | Clinical | Rock Creek, Roskamp Institute | Alzheimer Disease; Inflammation; Smoking Cessation; Thyroiditis, Autoimmune; Tobacco Use Disorder | Details |
| Tarenflurbil spraygel (MIKA Pharma) | Clinical | Galen Ltd, Mika Pharma Gmbh | Arthritis, Rheumatoid; Dermatitis, Atopic; Inflammation; Pain; Skin Diseases | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Glucosamine Hydrochloride | Approved | Dona, Xicil, Dolenio, Dona 200-S, Viartril-S | Mainland China | Osteoarthritis | Bright Future Pharmaceutical Laboratories Ltd | 2004-03-17 | Chronic Periodontitis; Insulin Resistance; Obesity; Osteoarthritis | Details | ||
| Charcoal | AST-120; MP-146 | Approved | Kureha Co | Kremezin, Zysa, Kremezin Fine Granules | Japan | Kidney Failure, Chronic | Mitsubishi Tanabe Pharma | 1991-10-04 | Asthma; Gastroesophageal Reflux; Hepatic Encephalopathy; Inflammatory Bowel Diseases; Intestinal Fistula; Irritable Bowel Syndrome; Kidney Failure, Chronic; Pouchitis; Renal Insufficiency, Chronic | Details |
| Mepacrine hydrochloride | CBL-0102; CBLC-102; Curaxin CBLC-102 | Approved | Bayer AG | Atebrin, Maladin, Atabrine, Tenicridine | Lupus Erythematosus, Systemic; Giardiasis; Leishmaniasis; Malaria | Bayer AG | 1932-01-01 | Carcinoma, Renal Cell; Creutzfeldt-Jakob Syndrome; Giardiasis; Leishmaniasis; Lupus Erythematosus, Systemic; Malaria; Prostatic Neoplasms | Details | |
| Anapsos | EQA-00 | Approved | Asac Pharmaceutical International | Psoriacen | Psoriasis; Dermatitis, Atopic | Asac Pharmaceutical International | 1972-01-01 | Dermatitis, Atopic; Psoriasis | Details | |
| Metaxalone (Primus Pharmaceuticals) | Approved | Primus Pharmaceuticals Inc | United States | Muscle Spasticity | Primus Pharmaceuticals Inc | 2015-06-01 | Muscle Spasticity | Details | ||
| Acetylaconitine | Approved | Mainland China | Pain | Shaanxi Xingbang Pharmacevtical Co Ltd | 1985-01-01 | Pain | Details | |||
| Andrographolide/Sodium Hydrogen Sulfite | Approved | Bacterial Infections | Details | |||||||
| Glucosamine Hydrochloride/Chondroitin sulfate | Approved | Details | ||||||||
| Glucosamine Hydrochloride/Indomethacin | Approved | Mainland China | Spondylitis, Ankylosing; Spondylosis; Periarthritis; Arthritis, Rheumatoid; Arthritis | null | 1995-01-01 | Arthritis; Arthritis, Rheumatoid; Periarthritis; Spondylitis, Ankylosing; Spondylosis | Details | |||
| Glucosamine Hydrochloride/Dermatan sulfate | Approved | Details | ||||||||
| Iguratimod | T-614 | Approved | Jiangsu Simcere Pharmaceutical Co Ltd | 艾得辛, Colvet, Iremod, Kolbet, Careram | Mainland China | Arthritis, Rheumatoid | Hainan Simcere Pharmaceutical Co Ltd | 2011-08-15 | Arthritis, Rheumatoid; Graft vs Host Disease; Sjogren's Syndrome | Details |
| Anvirzel | Approved | Nerium Biotechnology Inc, Ozelle Pharmaceuticals Inc | Anvirzel | Neoplasms | Details |
- Molekülinformation
- Produktliste
- Inverkehr gebrachte Arzneimittelinformation
- Klinische Arzneimittelinformation
Teilen auf:
Online-Nachricht
Kontaktieren Sie uns
BettinastraBe 30, 60325 Frankfurt am Main